| Institution: | 1. Research Institute of Cardiovascular Diseases and Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People''s Republic of China;2. Department of Medicine, Guizhou Hospital of Fushan city, Fushan, Guangdong, People''s Republic of China;3. Department of Medicine, Sixth Hospital of Nanchang city, Nanchang, Jiangxi, People''s Republic of China;4. Statistic Teaching Group, Fuzhou Medical College of Nanchang University, Fuzhou, Jiangxi, China;1. Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;2. Pfizer Research and Development Center, Shanghai, China;3. Pfizer Inc, New York, NY, USA;1. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA;2. Division of Nephrology, Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, USA;1. Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University, New York, NY;2. Department of Health Policy & Management, Mailman School of Public Health, Columbia University, New York, NY;3. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL |
